Exact Mass: 435.22300640000003
Exact Mass Matches: 435.22300640000003
Found 150 metabolites which its exact mass value is equals to given mass value 435.22300640000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Fosinoprilat
C23H34NO5P (435.2174484000001)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Valsartan
Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Cadabicine
C25H29N3O4 (435.21579540000005)
Cadabicine is found in fruits. Cadabicine is an alkaloid from the stem bark of the famine food Cadaba farinosa (luquata sigmama). Alkaloid from the stem bark of the famine food Cadaba farinosa (luquata sigmama). Cadabicine is found in fruits.
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
Valsartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1075 CONFIDENCE standard compound; INTERNAL_ID 1112 CONFIDENCE standard compound; INTERNAL_ID 8608 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2583 INTERNAL_ID 1112; CONFIDENCE standard compound Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Ala Lys Met Ser
Ala Lys Ser Met
Ala Met Lys Ser
Ala Met Ser Lys
Ala Ser Lys Met
Ala Ser Met Lys
Cys Lys Ser Val
Cys Lys Val Ser
Cys Ser Lys Val
Cys Ser Val Lys
Cys Val Lys Ser
Cys Val Ser Lys
Phe Gly Gly Arg
C19H29N7O5 (435.22300640000003)
Phe Gly Arg Gly
C19H29N7O5 (435.22300640000003)
Phe Arg Gly Gly
C19H29N7O5 (435.22300640000003)
Gly Phe Gly Arg
C19H29N7O5 (435.22300640000003)
Gly Phe Arg Gly
C19H29N7O5 (435.22300640000003)
Gly Gly Phe Arg
C19H29N7O5 (435.22300640000003)
Gly Gly Arg Phe
C19H29N7O5 (435.22300640000003)
Gly Lys Met Thr
Gly Lys Thr Met
Gly Met Lys Thr
Gly Met Thr Lys
Gly Arg Phe Gly
C19H29N7O5 (435.22300640000003)
Gly Arg Gly Phe
C19H29N7O5 (435.22300640000003)
Gly Thr Lys Met
Gly Thr Met Lys
Lys Ala Met Ser
Lys Ala Ser Met
Lys Cys Ser Val
Lys Cys Val Ser
Lys Gly Met Thr
Lys Gly Thr Met
Lys Met Ala Ser
Lys Met Gly Thr
Lys Met Ser Ala
Lys Met Thr Gly
Lys Ser Ala Met
Lys Ser Cys Val
Lys Ser Met Ala
Lys Ser Thr Thr
Lys Ser Val Cys
Lys Thr Gly Met
Lys Thr Met Gly
Lys Thr Ser Thr
Lys Thr Thr Ser
Lys Val Cys Ser
Lys Val Ser Cys
Met Ala Lys Ser
Met Ala Ser Lys
Met Gly Lys Thr
Met Gly Thr Lys
Met Lys Ala Ser
Met Lys Gly Thr
Met Lys Ser Ala
Met Lys Thr Gly
Met Ser Ala Lys
Met Ser Lys Ala
Met Thr Gly Lys
Met Thr Lys Gly
Arg Phe Gly Gly
C19H29N7O5 (435.22300640000003)
Arg Gly Phe Gly
C19H29N7O5 (435.22300640000003)
Arg Gly Gly Phe
C19H29N7O5 (435.22300640000003)
Ser Ala Lys Met
Ser Ala Met Lys
Ser Cys Lys Val
Ser Cys Val Lys
Ser Lys Ala Met
Ser Lys Cys Val
Ser Lys Met Ala
Ser Lys Thr Thr
Ser Lys Val Cys
Ser Met Ala Lys
Ser Met Lys Ala
Ser Thr Lys Thr
Ser Thr Thr Lys
Ser Val Cys Lys
Ser Val Lys Cys
Thr Gly Lys Met
Thr Gly Met Lys
Thr Lys Gly Met
Thr Lys Met Gly
Thr Lys Ser Thr
Thr Lys Thr Ser
Thr Met Gly Lys
Thr Met Lys Gly
Thr Ser Lys Thr
Thr Ser Thr Lys
Thr Thr Lys Ser
Thr Thr Ser Lys
Val Cys Lys Ser
Val Cys Ser Lys
Val Lys Cys Ser
Val Lys Ser Cys
Val Ser Cys Lys
Val Ser Lys Cys
Cadabicine
C25H29N3O4 (435.21579540000005)
DANSYL-GAMMA-AMINO-N-BUTYRIC ACID CYCLOHEXYLAMMONIUM SALT
C22H33N3O4S (435.2191658000001)
4-NITROPHENYL PHOSPHATE DI(CYCLOHEXYLAMINE) SALT MONOHYDRATE
4-Nitrophenyl phosphate,bis(cyclohexylammonium) salt hydrate
(22Z)-4-hydroxy-2-oxa-11,16,20-triazatricyclo[22.2.2.13,7]nonacosa-1(26),3,5,7(29),8,22,24,27-octaene-10,21-dione
C25H29N3O4 (435.21579540000005)
N,N-dibutyl-2-[[2-(1,3-dioxo-2-isoindolyl)-1-oxoethyl]amino]benzamide
C25H29N3O4 (435.21579540000005)
2-Cyclopentyl-4-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-9-methyl-1-pyrido[3,4-b]indolone
C25H29N3O4 (435.21579540000005)
N-(2-furanylmethyl)-N-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]butanediamide
(1S,9R,10R,11R)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H29N3O4 (435.21579540000005)
[(1S)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
1-[(2S,3R)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
[(1R)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(3R,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(4-fluorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(1R,9S,10S,11S)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H29N3O4 (435.21579540000005)
1-[(1S)-1-(hydroxymethyl)-7-methoxy-2-[(2-methoxyphenyl)methyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C25H29N3O4 (435.21579540000005)
1-[(2S,3S)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
1-[(2R,3R)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-[(2-methoxyphenyl)methyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C25H29N3O4 (435.21579540000005)
2-[Bis(phenylmethyl)amino]-1-(4-phenylmethoxyphenyl)-1-propanone
N-Pentanoyl-N-{[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
7-[2-(5-amino-2,2-dimethylchromen-6-yl)-2-oxoethyl]-9-hydroxy-11-(prop-1-en-2-yl)-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
C25H29N3O4 (435.21579540000005)
(22z)-2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(8e,22e)-2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(1r,7r,11r)-7-[2-(5-amino-2,2-dimethylchromen-6-yl)-2-oxoethyl]-9-hydroxy-11-(prop-1-en-2-yl)-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
C25H29N3O4 (435.21579540000005)
(3s,5s)-5-[(3s,8s,9r,9as)-8-hydroxy-9-[(2s)-1-(5-hydroxy-3-methoxy-4-methylfuran-2-yl)-1-oxopropan-2-yl]-octahydro-1h-pyrrolo[1,2-a]azepin-3-yl]-3-methyloxolan-2-one
C23H33NO7 (435.22569080000005)
2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(5z)-5-{1-hydroxy-2-[8-hydroxy-3-(4-methyl-5-oxooxolan-2-yl)-octahydro-1h-pyrrolo[1,2-a]azepin-9-yl]propylidene}-4-methoxy-3-methylfuran-2-one
C23H33NO7 (435.22569080000005)